Emerson Electric's (EMR) ACCE composite score moved from 56 to 66, a 10-point jump that puts the stock in meaningfully stronger territory on our model. A move of that size in a single update typically reflects improvement across at least one or two of the four subscores — Growth, Value, Quality, and Momentum — rather than a small drift across all of them.
Looking at where EMR sits today, the current subscore breakdown is: Quality 79, Momentum 76, Growth 56, and Value 51. Quality and Momentum are the clear strengths here. A 10-point composite gain of this size most likely reflects a meaningful lift in one of those already-strong areas, or a catch-up move in Growth or Value that pulled the composite higher.
The fundamental backdrop gives some clues. Year-over-year earnings growth came in at +23.0% against revenue growth of +7.0%, which signals that EMR is expanding margins, not just top-line volume. That kind of earnings leverage tends to feed directly into Quality and Growth subscores. The net margin sits at 13.8% and ROE at 12.8% — solid numbers for an industrial company — which helps explain why Quality already scores 79. If earnings quality improved or free cash flow conversion strengthened, that alone could push the composite up by several points.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
Momentum at 76 reflects the stock's real-world price action: EMR has returned +20.3% over the past year, trading at $159.69 as of August 10, 2026. Strong price momentum tends to compound in our model when it aligns with improving fundamentals, which appears to be happening here.
What it means
The 10-point score gain is a positive signal, but the full picture deserves some scrutiny. The 6-model fair value estimate sits at $99.67, which is 37.6% below the current price of $159.69. That gap is significant and is almost certainly what's keeping the Value subscore at a modest 51. The trailing P/E of 34.6 is elevated for an industrial, though the forward P/E of 22.1 suggests the market is pricing in continued earnings growth.
The analyst consensus target of $170.07 implies roughly 6.5% upside from current levels — a much narrower gap than our fair-value models show. That divergence between analyst targets and model-based fair value is worth watching.
The latest earnings report for Q3 FY2026 came in essentially in line with expectations. The score improvement, then, is less about a blowout quarter and more about the cumulative picture: strong quality metrics, solid momentum, and earnings growing faster than revenue.
EMR's 1.4% dividend yield adds a modest income component, though it's not the primary driver of the score move.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
